KLOW Peptide Blend (80mg)

KLOW is a four-peptide research blend containing GHK-Cu, BPC-157, TB-500 and KPV in one lyophilised vial. This product is listed as KLOW 80mg. The key ingredient difference from GLOW is the inclusion of KPV; the name does not describe a finished skincare product or a proven recovery treatment.

The KLOW 80 laboratory report #200491, analysed by Janoshik on 9 July 2026, records 57.50mg GHK-Cu, 12.31mg BPC-157, 12.61mg TB-500 (TB4) and 12.72mg KPV in the tested sample, totalling 95.14mg. The 57.50mg GHK-Cu result includes 50.65mg GHK and 6.85mg copper; those are parts of that result, not extra ingredients to add to the total. These laboratory measurements are distinct from the 80mg listed vial size. The report does not document the manufacturer’s target split or verify the amount in every vial.

Claims about KLOW peptide benefits commonly refer to collagen, tissue repair and inflammatory signalling. The evidence linked here concerns separate ingredients: a fibroblast-culture study of GHK-Cu examined collagen synthesis, a study of BPC-157 in rat tendon cells and tissue explants examined cell migration and survival, and a KPV study in cultured cells and mouse colitis models examined inflammatory signalling. None tested this four-component KLOW vial. These findings do not establish benefits for the combined product, prove that the ingredients work better together, or show that KLOW treats injuries, gut conditions or skin ageing in people.

KLOW contains GHK-Cu, BPC-157, TB-500 and KPV. GLOW 50mg and GLOW 70mg list the first three compounds without KPV. Compare the individual component measurements in each product’s public laboratory report as well as its listed vial size. Adding KPV changes the composition; it does not establish that KLOW is a stronger or more effective version of GLOW.

KPV stands for lysine-proline-valine, a three-amino-acid peptide. It adds a separate compound relevant to inflammatory-signalling research: a KPV study in cultured cells and mouse colitis models investigated how cells take up KPV and respond to it. That study used KPV, not KLOW, so it does not demonstrate an added benefit from including KPV in this blend.

KLOW is supplied as a lyophilized powder and should be reconstituted with bacteriostatic water (BAC water) immediately before use. Add BAC water slowly to the vial using a sterile syringe, directing the liquid down the inside wall. Gently swirl to dissolve — do not shake. Once reconstituted, store at 2–8°C and use within 8–12 weeks. For a full step-by-step walkthrough, see our complete peptide reconstitution guide.

Store lyophilized KLOW vials at -20°C, protected from light and moisture. After reconstitution with bacteriostatic water, refrigerate at 2–8°C and use within 8–12 weeks. Do not freeze the reconstituted solution.

KLOW Peptide Blend (80mg) is listed through Aussie Peptides for domestic delivery across Australia. Check the live availability on this page before ordering. The KLOW 80 laboratory report #200491 is available to read before purchase and records the measured amounts in the tested sample.

KLOW Peptide Blend (80mg) is currently in stock at Aussie Peptides and available for domestic dispatch across Australia. KLOW Peptide Blend (80mg) is priced at $199.99 per vial at Aussie Peptides. All orders ship domestically within Australia, and batch CoAs are available in our CoA library.

When KLOW Peptide Blend (80mg) is in stock, add it to your cart and complete checkout on the Aussie Peptides website. Orders are fulfilled domestically and shipped with tracking across Australia. Review the composition and public laboratory report when selecting material for laboratory research.